H1 Round Up: The haves and the have-nots

Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…

H1 Round Up: The haves and the have-nots

Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…

ADA/EASL eBook

June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…

ADA/EASL eBook

June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…